Cathepsin K inhibitors, 2000 – 2004

Bibliography

• BERTI PJ, STORER AC: Alignment/ phylogeny of the papain superfamily of cysteine proteases. J. Mol Biol. (1995) 246(2):273–283.
   PubMedGoogle Scholar
• LEUNG D, ABBENANTE G, FAIRLIE DP: Protease inhibitors: current status and future prospects. J. Med. Chem. (2000) 43(3):305–341.
   PubMed Web of Science ®Google Scholar
• LALONDE JM, ZHAO B, JANSON CA et al.: The crystal structure of human procathepsin K. Biochemistry (1999) 38(3):862–869.
   PubMedGoogle Scholar
• MCQUENEY MS, AMEGADZIE BY, D'ALESSIO K et al.: Autocatalytic activation of human cathepsin K. J. Biol. Chem. (1997) 272(21):13955–13960.
   Google Scholar
• TEZUKA K, TEZUKA Y, MAEJIMA A et al.: Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J. Biol. Chem. (1994) 269(2):1106–1109.
   PubMedGoogle Scholar
• INAOKA T, BILBE G, ISHIBASHI 0 et al.: Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem. Biophys. Res. Commun. (1995) 206(1):89–86.
   Google Scholar
• BLAIR HC, TEITELBAUM SL, GHISELLI R, GLUCK S: Osteoclastic bone resorption by a polarized vacuolar proton pump. Science (1989) 245(4920):855–857.
   PubMed Web of Science ®Google Scholar
• GARNERO P, BOREL 0, BYRJALSEN I et al.: The collagenolytic activity of Cathepsin K is unique among mammalian proteinases. j Biol. Chem. (1998) 273(48):32347–32352.
   Google Scholar
• ATLEY LM, MORT JS, LALUMIERE M, EYRE DR: Proteolysis of human bone collagen by Cathepsin K: characterisation of the cleavage sites generating the cross-linked N-telopeptide neoepitope. Bone (2000) 26(3):241–247.
   PubMed Web of Science ®Google Scholar
• HOU WS, BROMME D, ZHAO Y et al.: Characterisation of novel Cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Chit. Invest. (1999) 103(5):731–738.
   PubMed Web of Science ®Google Scholar
• SAFTIG P, HUNZIKER E, WEHMEYER 0 et al.: Impaired osteoclastic bone resorption leads to osteopetrosis in Cathepsin K-deficient mice. Proc. Natl. Acad. Sci. USA. (1998) 95(23):13453–14358.
   Google Scholar
• •First paper describing catK -/- mice.
   Google Scholar
• GOWEN M, LAZNER F, DODDS R et al.: Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Min. Bone Res. (1999) 14(10):1654–1663.
   PubMed Web of Science ®Google Scholar
• KLEEREKOPER M, AL-KHAYER F: Osteoporosis, overview. In: Encyclopedia of Endocrine Diseases (2004) 3:425–431.
   Google Scholar
• LINDSAY R, MEUNIER PJ: Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporosis Int. (1998) 8\(Supp1.4):S1–588.
   Google Scholar
• RODAN GA, MARTIN TJ: Therapeutic approaches to bone disease. Science (2000) 289(5484):1508–1514.
   PubMed Web of Science ®Google Scholar
• BERG C, NEUMEYER K, KIRKPATRICK P: Fresh from the pipeline: Teriparatide. Nat. Rev. Drug Discov. (2003) 2(4):257–258.
   PubMedGoogle Scholar
• INZERILLO AM, ZAIDI M: Osteoporosis: trends and intervention. Mount Sinai j Medicine (2002) 69(4):220–231.
   PubMedGoogle Scholar
• LARK MW, STROUP GB, JAMES IE et al.: A potent small molecule, nonpeptide inhibitor of Cathepsin K (SB-331750) prevents bone matrix resorption in the ovariectomized rat. Bone (2002) 30(5):746–753.
   PubMedGoogle Scholar
• STROUP GB, LARK MW VEBER DF et al.: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. j Bone Min. Res. (2001) 16(10):1739–1746.
   Google Scholar
• ••Paper describing effects of cathepsin Kinhibition on bone resorption in cynomolgus monkeys.
   Google Scholar
• ROBICHAUD J, OBALLA R, PRASIT P et al.: A novel class of non-peptidic biaryl inhibitors of human cathepsin K. J. Med. Chem. (2003) 46(17):3709–3727.
   PubMedGoogle Scholar
• •Development and profiling of non-peptidic nitrile-based inhibitor.
   Google Scholar
• Novartis company presentation, NY, USA (19/11/2003).
   Google Scholar
• SUKHOVA GK, ZHANG Y, PAN J-H et al.: Deficiency of cathepsin K reduces atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. (2003) 111(0:897–906.
   PubMedGoogle Scholar
• ••Evidence supporting the use of cathepsin Kinhibitors for the treatment of atherosclerosis.
   Google Scholar
• HOLM K: Primary and secondary prevention using lipid-lowering therapies. Cardiovasc. Nurs. (2000) 14(2):1–8.
   Google Scholar
• LITTLEWOOD-EVANS AJ, BILBE G, BOWLER Wet al.: The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. (1997) 57(23):5386–5390.
   Google Scholar
• BRUBAKER KD, VESSELLA RL, TRUE LD, THOMAS R, COREY E: Cathepsin K mRNA and protein expression in prostate cancer progression. J. Bone Min. Res. (2003) 18(2):222–230.
   PubMedGoogle Scholar
• RULLMAN JAG, BELLIDO MN, VAN DUIJNEN PT: The active site of papain. All-atom study of interactions with protein matrix and solvent. J. MoL Biol. (1989) 206(1):101–118.
   Google Scholar
• McGRATH ME, KLAUS JL, BARNES MG, BROMME D: Crystal structure of human cathepsin K complexed with a potent inhibitor. Nat. Struct. Biol. (1997) 4(2):105–109.
   PubMedGoogle Scholar
• MARQUIS RW, RU Y, LOCASTRO SM et al.: Azepanone-based inhibitors of human and rat cathepsin K. J. Med. Chem. (2001) 44(9):1380–1395.
   PubMedGoogle Scholar
• •Paper describing an extensive use of biostructural information to improve potency and bioavailability of azepanone analogues.
   Google Scholar
• BROMME D, KLAUS JL, OKAMOTO K, RASNICK D, PALMER JT: Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: 52/P2 specificity of human cathepsin 02 in comparison with cathepsin S and L. Biochem. J. (1996) 315(1):85–89.
   PubMedGoogle Scholar
• RANRAKOKKO J, ARO HT, SAVONTAUS M et al.: Mouse cathepsin K: cDNA cloning and predominant expression of the gene in osteoclasts, and in hypertrophying chondrocytes during mouse development. FEBS Lett. (1996) 393(2-3):307–313.
   PubMedGoogle Scholar
• CATALANO JG, DEATON DN, FURFINE ES et al.: Exploration of the P1 SAP. of aldehyde cathepsin K inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(1):275–278.
   PubMedGoogle Scholar
• MCGRATH ME, SPRENGLER PA, HILL CM et al.: Peptide ketobenzoxazole inhibitors bound to cathepsin K. Biochemistry (2003) 42(51):15018–15028.
   PubMedGoogle Scholar
• THOMPSON SK, HALBERT SM, DESJARLAIS RL et al.: Structure-based design of non-peptide, carbohydrazide-based cathepsin K inhibitors. Bioorg. Med. Chem. (1999) 7(4):599–605.
   PubMedGoogle Scholar
• INUI T, ISHIBASHI 0, TETSUYA 0 et al.: Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption./ Biol Chem. (1997) 272(13):8109–8112.
   Google Scholar
• YAMASHITA DS, DODDS RA: Cathepsin K and the design of inhibitors of cathepsin K. Curr. Pharm. Des. (2000) 6(1):1–24.
   PubMedGoogle Scholar
• ••Good combination review summarisingcathepsin K biology, osteoporosis in vitro validation data and design of early inhibitors.
   Google Scholar
• MARQUIS RW: Chapter 28. In: Inhibition of cysteine proteases. Ann. Rep. Med. Chem. (2000) 35:309–320.
   Google Scholar
• LECAILLE F, KALETA J, BROMME D: Human and parasitic papain-like cysteine proteases: Their role in physiology and pathology and recent developements in inhibitor design. Chem. Rev. (2002) 102(12):4459–4488.
   PubMed Web of Science ®Google Scholar
• ••Extensive review of cysteine proteases andtheir inhibitors.
   Google Scholar
• LEUNG-TOUNG R, WANREN L, TAM TF, KARIMIAN K: Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Chem. (2002) 9(9):979–1002.
   PubMed Web of Science ®Google Scholar
• KIM W, KANG K: Recent developments of cathepsin inhibitors and their selectivity. Expert Opin. Ther Patents (2002) 12(3):419–431.
   Web of Science ®Google Scholar
• DESJARLAIS RL, YAMASHITA DA, OH H-J et al.: Use of X-ray co-crystal structure and molecular modelling to design potent and selective non-peptide inhibitors of cathepsin K. J. Am. Chem. Soc. (1998) 120(35):9114–9115.
   Google Scholar
• MATSUMOTO K, MIZOUE K, KITAIVIURA K et al.: Structural basis of inhibition of cysteine proteases by E-64 and its derivatives. Biopolymers (1999) 51(1):99–107.
   PubMed Web of Science ®Google Scholar
• VOTTA BJ, LEVY MA, BADGER A et al.: Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Min. Res. (1997) 12(9):1396–1406.
   PubMed Web of Science ®Google Scholar
• MARQUIS RW, YAMASHITA DS, RU Y et al.: Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K. J. Med. Chem. (1998) 41(19):3563–3567.
   PubMedGoogle Scholar
• FALGUEYRET J-P, OBALLA R, OKAMOTO 0 et al.: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. J. Med. Chem. (2001) 44(1):94–104.
   Google Scholar
• CATALANO JG, DEATON DN, LONG ST: Design of small molecule ketoamide-based inhibitors of cathepsin K. Bioorg. Med. Chem. Lett. (2004) 14(3):719–722.
   PubMedGoogle Scholar
• ALTMANN E, RENAUD J, GREEN J et al.: Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors. J. Med. Chem. (2002) 45(12):2352–2354.
   PubMedGoogle Scholar
• AMOS HE, PARK BK: Understanding immunotoxic drug reactions. Immunotoxicol Immunopharmacol Raven Press, NY (1985):207–228.
   Google Scholar
• YAMASHITA DS, SMITH WW, ZHAO B et al.: Structure and design of potent and selective cathepsin K inhibitors. J . Am. Chem. Soc. (1997) 119:11351–11352.
   Web of Science ®Google Scholar
• ABDEL-MEGUID SS, ZHAO B, SMITH WW: Rational approaches to inhibition of human osteoclast cathepsin K and treatment of osteoporosis. ACS Symposium Series (1999) 719:141–152.
   Google Scholar
• FEN WICK AE, GRIBBLE AD, IFE RJ, STEVENS N, WITHERINGTON J: Diastereoselective synthesis, activity and chiral stability of cyclic alkoxyketone inhibitors of cathepsin K. Bioorg. Med. Chem. Lett. (2001) 11(2):199–202.
   PubMedGoogle Scholar
• TAVARES FX, BONCEK V, DEATON DN et al.: Design of potent, selective and orally bioavailable inhibitors of cysteine protease cathepsin K. J . Med. Chem. (2004) 47(3):588–599.
   PubMedGoogle Scholar
• LEWIS CA: WOLFENDEN R: Thiohemiacetal formation by inhibitory aldehydes at the active site of papain. Biochemistry (1977) 16(22):4890–4895.
   PubMedGoogle Scholar
• MOON JB, COLEMAN RS, HANZLIK RP: Reversible covalent inhibition of papain by a peptide nitrile. Carbon-13 NMR evidence for a thioimidate ester adduct. J. Am. Chem. Soc. (1986) 108(6):1350–1351.
   Google Scholar
• ROBICHAUD J, BAYLY C, OBALLA, R et al.: Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(16):4291–4295.
   PubMedGoogle Scholar
• PALMER J: Celera Genomics, Screentech protease inhibitors meeting, San Diego, USA (March 2004).
   Google Scholar
• 4th Sci-RSC symposium on proteinase inhibitor design, London, (May 2004).
   Google Scholar
• RYDZEWSKI R, BRYANT C, OBALLA R et al.: Peptidic 1-cyanopyrrolidines: Synthesis and SAP. of a series of potent, selective cathepsin inhibitors. Bioorg. Med. Chem. (2002) 10(10):3277–3284.
   Google Scholar
• ALTMAN E, GREEN J, TINTELNOT-BLOMLEY M: Arylaminoethyl amides as inhibitors of the cysteine protease inhibitor cathepsin K - investigating P,' substituents. Bioorg-. Med. Chem. Lett. (2003) 13(12):1997–2001.
   PubMedGoogle Scholar
• •Useful discussion of proposed binding mode and SAR of aminoethylaryl amide inhibitors.
   Google Scholar
• KIM TS, HAGUE AB, LEE TI et al.: (4-Piperidinylphenypaminoethyl amides as a novel class of non-covalent cathepsin K inhibitors. Bioorg-. Med. Chem. Lett. (2004) 14(1):87–90.
   PubMedGoogle Scholar
• •Demonstration of the ex vivo activity of the arylaminoethyl amide inhibitors in a relevant functional assay.
   Google Scholar
• NORMAN P: Highlights from the third RSC-SCI symposium on proteinase inhibitor design. Drug News Prospect (2002) 15(6):372–382.
   PubMedGoogle Scholar
• REES DC, CONGREVE M, MURRAY CW, CARR R: Fragment based lead discovery. Nat. Rev. Drug Discov. (2004) 3(8):660–672.
   PubMedGoogle Scholar